QualityStocksNewsBreaks – VolitionRx Limited (NYSE American: VNRX) Study Shows Nu.Q Vet Feline Test Accurately Detects Lymphoma in Cats
VolitionRx (NYSE American: VNRX), a multinational epigenetics company, announced results from a clinical study demonstrating high accuracy of its Nu.Q Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, meaning no false positives, the blood-based assay detected more than 80% of feline lymphomas, supporting development of what the company expects to be the world’s first simple and affordable liquid biopsy test for feline cancer. The company stated that feline cancer has historically been difficult to diagnose early, often requiring invasive biopsies or costly imaging after symptoms have progressed, and noted that…
